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Phosphate plays a central role in the pathophysiology of
CKD-MBD and the progression of chronic kidney disease
(CKD) and contributes to the disproportionate cardiovascu-
lar risk faced by patients with CKD. Adaptation of nephrons
attempting to preserve phosphate homeostasis requires
endocrine tradeoﬀ that fuel adverse events of hyperphospha-
temia in CKD—secondary hyperparathyroidism, calcium
and vitamin D derangements, vascular calciﬁ cation, and
metabolic bone disorder.
In fact, in advancing CKD there is a multitude of bio-
chemical, physiological, and clinical alterations, and mecha-
nisticunderstandingofsecondaryhyperparathyroidism,vas-
cular calciﬁcation, and regulation of phosphate metabolism
in CKD has advanced signiﬁcantly in the past ﬁve decades.
The principal hormones that regulate renal phosphate han-
dling are parathyroid hormone (PTH), which is produced by
the parathyroid gland, and ﬁbroblast growth factor (FGF)-
23, which is produced by osteocytes and osteoblasts in bone.
In healthy individuals, increasing serum phosphate concen-
tration induces secretion of PTH and FGF-23, and Kloto
decline.
It has been established (and now accepted by nephrolo-
gists) that observational studies strongly suggest that phos-
phorus is associated with cardiovascular risk, and deﬁni-
tive prospective animal studies are supportive. However,
prospective studies demonstrating that modulation of the
putative risk factor aﬀects clinical outcomes are lacking, and
phosphorus, as yet, does not qualify as a cardiovascular risk
factor.
This special issue provides an identiﬁcation of the
complex mechanisms that determine the phosphorus and
calcium metabolism in CKD-3 and CKD-4; a verify the as-
sociation of serum phosphate and related factors in ESRD-
related vascular calciﬁcation.
Ithasalsoaddressedmineralmetabolisminpatientswith
CKGintheEraofKDIGOGuidelines,theeﬀectofvitaminD
on clinical outcomes in chronic kidney disease, and the eﬀect
of paricalcitol on vascular calciﬁcation and cardiovascular
disease in uremia.
Finally, were also discussed the eﬀect of the use of non-
calcium-phosphate binders in the control of vascular cal-
ciﬁcations; the clinical signiﬁcance of FGF-23 in patients
with CKD, the the relationship between arterial stiﬀness
and vascular damage; the treatment of severe metastatic
calciﬁcation and calciphylaxis in dialysis patients; the clinical
impact of hypercalcemia in kidney transplant patients.
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